Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04188951 · ClinicalTrials.gov registry record · Early Phase 1
HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer
A Early Phase 1 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT04188951 is a Early Phase 1 study that has completed, run by Henry Ford Health System. The registered enrollment target is 10 participants.
The verdict
NCT04188951, a Early Phase 1 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The study is a pilot study to explore the feasibility and efficacy of immunotherapy following salvage surgery for recurrent head and neck cancer.
Interventions
- DRUG Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-10-04 |
| Est. Completion | 2024-05-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04188951
The ClinicalTrials.gov registry entry for NCT04188951 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] is the first listed.
NCT04188951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04188951 about?
NCT04188951 is a clinical study titled "HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer". The study is a pilot study to explore the feasibility and efficacy of immunotherapy following salvage surgery for recurrent head and neck cancer.
What is the current status of trial NCT04188951?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-10-04. Estimated completion is 2024-05-08.
What interventions are being tested in trial NCT04188951?
The interventions under investigation include: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] (DRUG).
Who is sponsoring clinical trial NCT04188951?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.